Gainers

• Virax Biolabs Group (NASDAQ:VRAX) shares rose 178.9% to $8.87 during Thursday's regular session. The market value of their outstanding shares is at $2.5 million.
• Forte Biosciences (NASDAQ:FBRX) stock rose 55.48% to $32.0. The market value of their outstanding shares is at $421.4 million.
• First Tracks (NASDAQ:TRAX) shares rose 43.66% to $29.84. The market value of their outstanding shares is at $724.7 million.
• Circle8 Group (NASDAQ:CIRC) stock moved upwards by 24.39% to $0.75. The company's market cap stands at $54.2 million.
• Evogene (NASDAQ:EVGN) stock increased by 22.16% to $0.51. The market value of their outstanding shares is at $5.0 million.
• TransCode Therapeutics (NASDAQ:RNAZ) shares moved upwards by 18.15% to $9.31. The company's market cap stands at $7.4 million.

Losers

• Ionis Pharmaceuticals (NASDAQ:IONS) shares declined by 23.8% to $64.33 during Thursday's regular session. The market value of their outstanding shares is at $13.9 billion.
• AEON Biopharma (AMEX:AEON) shares decreased by 22.9% to $0.54. The market value of their outstanding shares is at $18.4 million.
• Tvardi Therapeutics (NASDAQ:TVRD) shares fell 22.4% to $3.88. The market value of their outstanding shares is at $46.9 million.
• ABVC BioPharma (NASDAQ:ABVC) stock declined by 20.89% to $1.6. The company's market cap stands at $52.5 million.
• ZeroStack (NASDAQ:ZSTK) stock declined by 19.88% to $2.29. The company's market cap stands at $6.8 million.
• Catheter Precision (AMEX:VTAK) shares declined by 17.16% to $1.14. The company's market cap stands at $4.9 million. See Also: www.benzinga.com/money/best-healthcare-stocks/

This article was generated by Benzinga's automated content engine and reviewed by an editor.

Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.